 Lower urinary tract symptoms (LUTS) are highly prevalent, and nocturia is one of the most bothersome symptom of LUTS. Nocturia is defined as 'waking to void 1 or more times a night followed by sleep'. 1 In women, nocturia is often associated with overactive bladder (OAB). 2  The most frequent cause of nocturia is nocturnal polyuria (NP), defined as increased urine production at night (i.e. ≥33% of 24 hour urine volume). 3  Nocturia severely affects the health-related quality of life (HRQoL) as it disrupts sleep, leading to daytime tiredness, cognitive dysfunction, mood changes, risk of falls/fractures, and even mortality. 4  Currently, there is limited information on the relationship between NP disease severity as defined by the number of nocturnal voids, and the HRQoL tools, accounting for patients and disease characteristics.
− Overall Impact score (Q12: does nocturia presently impact your life?). NI Diary © Total and Overall Impact scores are standardised from 0 to 100 (best to worst QoL).
Statistical Analyses
 The pooled baseline values in EQ-5D VAS, EQ-5D index (US weights), NI Diary © Total and Overall Impact scores were assessed.
This trial was sponsored by Ferring Pharmaceuticals. Medical writing support was provided by Tania Peshin (Tata Consultancy Services), funded by Ferring.  This analysis shows that nocturia due to NP negatively impacts the HRQoL, however, there were no significant differences between patients with more and less severe disease, though a trend was observed in this limited sample.
 The NI Diary © Total score difference between the severe and less severe patients was slightly above 5 points, a difference which has been estimated to be clinically meaningful. 6  EQ-5D-5L TM used to measure impact of nocturia on HRQoL was shown to be relatively insensitive to urinary disease.
Patients
 The trial included a total of 106 patients, of whom 47 patients were identified as having NP. Of these, a total of 41 patients belonging to the NP subgroup completed these instruments and were included in this post-hoc analysis. They were categorised based on NP disease severity (2-3 nocturnal voids [n=27]; ≥4 nocturnal voids [n=14]). Demographic and baseline characteristics of NP subgroup are presented in Table 1 .
Study Assessments
 EQ-5D Index values (unadjusted) fell from 0.88 in patients with 2-3 nocturnal voids to 0.81 in patients with ≥4 nocturnal voids, which did not differ significantly.
 EQ-5D Index values adjusted for age, body mass index, number of comorbidities and baseline nocturnal voids also showed a non-significant difference between the two groups (0.87 and 0.83 in patients with 2-3 nocturnal voids and ≥4 nocturnal voids, respectively; Figure 2 ).
 Adjusted EQ-5D VAS values were similar in both the groups (80.5 and 80.6 in patients with 2-3 nocturnal voids and ≥4 nocturnal voids, respectively).
 NI Diary © Total score increased with greater number of nocturnal voids (41.5 and 46.8 in patients with 2-3 nocturnal voids and ≥4 nocturnal voids, respectively). The difference between the two groups however was not significant (Figure 3) . 
